• About us
• Contact

Advertisement

Organisation › Details

Johnson & Johnson (JnJ) (Group)

Johnson & Johnson is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. The more than 250 Johnson & Johnson operating companies employ approximately 121,000 men and women in 57 countries and sell products throughout the world. *

 

	Start	1888-01-01 established?
	Industry	pharmaceutical
	Industry 2	diagnostics (medical/biological)
	Street	One Johnson & Johnson Plaza
	City	08933 New Brunswick, NJ
		Address record changed: 2020-12-02
Basic data	Employees	J: more than 100,0 (2017-01-26)
	Currency	USD
	Annual sales	82,584,000,000 (sales, consolidated (2020) 2020-12-31)
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Addex Therapeutics S.A.. (7/22/24). "Press Release: Addex’s Partner Discontinues ADX71149 Development in Epilepsy". Geneva....
• [2] Bright Peak Therapeutics AG. (6/11/24). "Press Release: Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials". Basel & San Diego, CA....
• [3] Numab Therapeutics AG. (5/28/24). "Press Release: Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis". H...
• [4] Addex Therapeutics S.A.. (4/29/24). "Press Release: Addex Provides Update on ADX71149 Phase 2 Epilepsy Study". Geneva....
• [5] Basel Area Business & Innovation. (4/26/24). "Press Release: Johnson & Johnson Opens Innovation Hub in Allschwil"....
• [6] Recursion Pharmaceuticals, Inc.. (4/16/24). "Press Release: Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer". Salt Lake City, UT....
• [7] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
• [8] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
• [9] Nanobiotix S.A.. (7/10/23). "Press Release: Nanobiotix Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3". Paris & Cambridge, MA....
• [10] Alia Therapeutics S.r.l.. (5/5/23). "Press Release: Alia Therapeutics Names Letizia Goretti as Chief Executive Officer". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.